Highlights•Non-efficacious preventative vaccines: gp120, Ad5 vector, DNA/Ad5.•Partially-
efficacious preventative vaccine: ALVAC-HIV/AIDSVAX® B/E gp120.•Clade C ALVAC/gp120 …

Many attempts have been made or are ongoing for HIV prevention and HIV cure. Many
successes are in the list, particularly for HIV drugs, recently proposed also for prevention …

Although HAART suppresses HIV replication, it is often unable to restore immune
homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated …

Background The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002,
Clinicaltrials. gov NCT00751595) was aimed at evaluating the immunogenicity and the …

Resistance to medication, adverse effects in the medium-to-long-term and cost all place
important limitations on lifelong adherence to combined antiretroviral therapy (cART). In this …

Therapeutic immunization of HIV-1-infected individuals with or without anti-retroviral therapy
is a new promising disease prevention. To induce a new cytotoxic TCD8 lymphocyte (CTL) …

Introduction: Tat, a key HIV virulence protein, has been targeted for the development of a
therapeutic vaccine aimed at cART intensification. Results from phase II clinical trials in Italy …

Use of Env in HIV vaccine development has been disappointing. Here we show that, in the
presence of a biologically active Tat subunit vaccine, a trimeric Env protein prevents in …

Each time the virus starts a new round of expression/replication, even under effective
antiretroviral therapy (ART), the transactivator of viral transcription Tat is one of the first HIV-1 …

After entry into the target cell, the human immunodeficiency virus type I (HIV) integrates into
the host genome and becomes a proviral eukaryotic transcriptional unit. Transcriptional …